Insilico Medicine is conducting a Phase I study in Australia, and Feng Ren serves as Co-CEO and Chief Scientific Officer.
2 reports, 1 independent
Updated Aug 12
Gone quiet
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Insilico Medicine is conducting a Phase I study in Australia, and Feng Ren serves as Co-CEO and Chief Scientific Officer.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Insilico Medicine
American biotechnology company
Nothing else this week.
-
Feng Ren
researcher (ORCID 0000-0001-9157-9182)
Nothing else this week.